For plaque psoriasis, you’ll start with a loading dose of 80 mg of Humira. One week after your loading dose, you’ll start taking 40 mg every other week. Humira is available in a starter kit ...

It also says it is more convenient because patients can self-administer Humira twice a month instead of once or twice a week for Enbrel. Enbrel was approved in April 2004 for psoriasis ...

Two adalimumab biosimilars (Amjevita and Imraldi) worked as well for moderate to severe psoriasis as the original brand-name product (Humira) for patients either starting or switching treatment ...

In early clinical trials, Abbott Laboratories’ drug for rheumatoid arthritis, Humira, is also showing promise as a treatment for the chronic skin condition psoriasis. Humira, which is already ...

Biosimilars for adalimumab (Humira) had similar efficacy and safety profiles for psoriasis when compared to the original. The meta-analysis appeared recently in the Journal of Dermatological ...

The new indication for Humira (adalimumab) is for patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy. It had previously been approved as a treatment ...

ABBOTT PARK, Ill., April 2 (UPI) -- Abbott said Monday it filed for approval of Humira as a psoriasis treatment in both the United States and Europe. The company simultaneously submitted a ...

Abbott Laboratories announced that the European Commission approved the marketing of Humira as a treatment for moderate to severe forms of the skin disorder plaque psoriasis, according to ...

Baxalta and Momenta Pharmaceuticals announced the beginning of a clinical trial of M923, a proposed biosimilar of Humira, in treating patients with chronic plaque psoriasis. The randomized ...

Among patients with moderate-to-severe psoriasis treated with Humira, correlations were found between leptin and metabolic syndrome and inflammation, and between resistin and inflammation and ...

Uncertainties remain about the real-world benefit of adalimumab biosimilars for psoriasis, limiting their widespread adoption. This analysis involving patients in the U.K. and Ireland provides ...